soul trial oral semaglutide cardiovascular outcomes nejm 2025 results New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj and (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis Oral Semaglutide Cuts Cardiovascular Risk

This medication is typically prescribed following a treatment care plan that includes diet and exercise to ensure health conditions are safely and properly managed

If you miss a dose and it has been less than four days since your scheduled injection, take the missed dose as soon as you remember

We use a fine needle to inject VOLUMA XC into the areas of your cheeks that need volume, resulting in immediate lifting and contouring

Together, these findings position GSH not only as a guardian of cellular integrity but also as a context-dependent determinant of cell death susceptibility and therapeutic vulnerability

O = Reduction in composite CV events (MACE) and their individual components

While public health experts and climate scientists argue about whether we should rely on livestock production systems to meet the nutritional demands of a growing global population while tackling climate change, those who produce our foodthe average farmerare struggling financially (Wiggins et al., 2010)